DEVELOP OF ANTIBODY FRAGM AS CONTR AGT FOR MRI OF ALZH?S DIS AMYLOID PLAQUES

开发抗体片段作为 ALZH 淀粉样斑块 MRI 的对照 AGT

• 批准号: 8362868
• 负责人: MICHAEL GARWOOD
• 金额: $ 3.03万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8362868
• 关键词: Alzheimer' s Disease; Amyloid; Antibodies; Blood; Brain; Contrast Media; Diagnostic; Early Diagnosis; Funding; Grant; Human; Image; Lead; Magnetic Resonance; Magnetic Resonance Imaging; Measures; Modification; Monoclonal Antibodies; NMR Spectroscopy; National Center for Research Resources; Nerve; Nervous system structure; Principal Investigator; Proteins; Research; Research Infrastructure; Resources; Senile Plaques; Source; Testing; Transgenic Mice; United States National Institutes of Health; cost; in vivo; molecular imaging; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The ability to target therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain/nerve barriers. In this project we are testing the hypothesis that modifications of an F(ab2)2 fragment of a monoclonal antibody (IgG4.1) against fibrillar human A¿42 can be used for the molecular imaging of amyloid plaques in Alzheimer's disease (AD) using high field strength magnetic resonance microimaging (MRMI) (9.4 T). The ability of this contrast agent to image plaques in vivo in AD transgenic mice may lead to early diagnosis of AD in humans and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供 该子项目的主要支持。 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源的子项目可能列出的总成本。 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 将治疗或诊断蛋白靶向神经系统的能力受到血脑/神经屏障的存在的限制。在该项目中，我们正在测试单克隆抗体 (IgG4) 的 F(ab2)2 片段的修饰这一假设。 .1) 对抗纤维状人类 A¿ 42 可用于使用高场强磁共振显微成像 (MRMI) (9.4 T) 对阿尔茨海默病 (AD) 中的淀粉样斑块进行分子成像。该造影剂在 AD 转基因小鼠体内对斑块进行成像的能力可能会导致。人类 AD 的早期诊断，还可以直接衡量目前正在开发的抗淀粉样蛋白疗法的疗效。